# EDGAR Filing Document

**Accession Number:** 0000816956
**File Stem:** 0002077096-26-000203
**Filing Date:** 2026-6
**Character Count:** 38268
**Document Hash:** c4b5c5fa1926e67748b1d8078f53db94
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002077096-26-000203.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0002077096-26-000203

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20260617

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CONMED Corp
- **CENTRAL INDEX KEY:** 0000816956
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 160977505
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39218
- **FILM NUMBER:** 261099236

**BUSINESS ADDRESS:**
- **STREET 1:** 11311 CONCEPT BOULEVARD
- **CITY:** LARGO
- **STATE:** FL
- **ZIP:** 33773
- **BUSINESS PHONE:** 727-214-2974

**MAIL ADDRESS:**
- **STREET 1:** 11311 CONCEPT BOULEVARD
- **CITY:** LARGO
- **STATE:** FL
- **ZIP:** 33773

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CONMED CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 17, 2026

**CONMED CORPORATION**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> <u>001-39218</u> <u>16-0977505</u> <br> (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)

<u>11311 Concept Blvd Largo, FL</u> <u>33773</u> <br> (Address of principal executive offices) (Zip code)

<u>(727) 392-6464</u>

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which registered |
| Common Stock, $0.01 par value CNMD | NYSE |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On June 17, 2026, CONMED Corporation (the "Company") announced that John E. Gallagher has been appointed to serve as the Company's Executive Vice President, Chief Financial Officer beginning July 15, 2026 (the "Effective Date"). Mr. Gallagher will also be the Company's principal financial officer and principal accounting officer.

Mr. Gallagher, age 53, will join the Company from Certara, Inc., a publicly traded pharmaceutical technology and services company, where he has served as Chief Financial Officer since April 2023. Prior to joining Certara, Mr. Gallagher served as Chief Financial Officer of Cue Health Inc., a publicly traded healthcare technology company, from 2021 to 2023. Prior to Cue Health, Mr. Gallagher served as Senior Vice President, CFO of the Medical Segment and Treasurer of Becton, Dickinson & Co., a multinational medical technology company. Mr. Gallagher joined Becton Dickinson in 2012 as Corporate Treasurer and also served as Chief Accounting Officer during his time there. Prior to joining Becton Dickinson, Mr. Gallagher served in a variety of finance leadership positions at NBC Universal, General Electric Company and Ford Motor Company. Mr. Gallagher received his MBA from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh and a B.S. in Finance from Clemson University.

There are no arrangements or understandings between Mr. Gallagher and any other person pursuant to which he was appointed as Chief Financial Officer. There are no family relationships between Mr. Gallagher and any director or officer of the Company, nor does Mr. Gallagher have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In connection with his appointment, Mr. Gallagher and the Company entered into a letter agreement that sets forth the terms and conditions of his employment (the "Letter Agreement"). Mr. Gallagher's annual base salary will be $650,000, and he will be eligible for an annual cash bonus targeted at 85% of his base salary, subject to achievement of certain performance metrics. The Letter Agreement also provides for grants to Mr. Gallagher on the Effective Date pursuant to the Company's 2025 Long-Term Incentive Plan (the "2025 Long-Term Incentive Plan") of (a) (i) options to purchase common shares of the Company with a grant value of $575,000, (ii) restricted stock units with grant value of $1,150,000 and (iii) performance stock units with a grant value of $575,000 and (b) restricted stock units with a grant value of $1,500,000, subject to the approval of the Company's Compensation Committee, as a make-whole in connection with certain equity awards forfeited from a prior employer. In addition, Mr. Gallagher will receive a one-time cash bonus payment of $34,750 if he remains employed by the Company on December 31, 2026.

Mr. Gallagher will also participate in the CONMED Corporation Executive Severance Plan (the "Severance Plan"). Under the Severance Plan, if Mr. Gallagher is terminated by the Company other than for Cause (as defined in the Severance Plan) prior to, or more than two years following, a Change in Control (as defined in the Severance Plan) and signs a customary release of claims, Mr. Gallagher will receive: (i) a lump sum cash payment equal to 1.5 times his base salary; (ii) a lump sum cash payment equal to 1.5 times the average of his Annual Incentive Awards (as defined in the Severance Plan) earned for the two completed fiscal years immediately preceding the year of termination; and (iii) continued participation in the Company's group health plans for the maximum period permitted under COBRA. If, during the two-year period following a Change in Control, Mr. Gallagher is terminated by the Company other than for Cause or Mr. Gallagher resigns for Good Reason (as defined in the Severance Plan) and signs a customary release of claims, Mr. Gallagher will receive: (i) a lump sum cash payment equal to 2.5 times his base salary; (ii) a lump sum cash payment equal to 2.5 times the average of his Annual Incentive Awards earned for the three completed fiscal years immediately preceding the year of termination; and (iii) continued participation in the Company's group health plans for the maximum period permitted under COBRA. In the event that any payments or benefits payable to Mr. Gallagher would constitute "parachute payments" within the meaning of Section 280G of the Internal Revenue Code (the "Code") and would be subject to the excise tax imposed by Section 4999 of the Code, such payments and benefits will be either delivered in full or reduced to the lesser extent that would result in no portion being subject to such excise tax, whichever results in the greater after-tax benefit to Mr. Gallagher.

The foregoing description of the Letter Agreement is not complete and is qualified in its entirety by reference to the full text of the Letter Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Upon the Effective Date, Patrick Beyer will cease to be the Company's Interim Principal Financial Officer, but he will continue to serve as the Company's President and Chief Executive Officer. In addition, Kimberly Lockwood will cease to be the Company's Interim Principal Accounting Officer, but she will remain Interim Corporate Controller and Senior Director, Financial Reporting and Controls.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

On June 17, 2026, the Company issued a press release announcing the matters described above, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished herewith pursuant to Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 10.1 | [Letter Agreement, dated May 28, 2026, by and between the Company and John E. Gallagher.](ea029501601ex10-1.htm) |
| 99.1 | [Press Release issued by CONMED Corporation dated June 17, 2026.](ea029501601ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 17, 2026 | CONMED CORPORATION | CONMED CORPORATION |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Registrant) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Registrant) |
|  | By: | /s/ Patrick Beyer |
|  | Name: | Patrick Beyer |
|  | Title: | President and Chief Executive Officer and Interim Principal Financial Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

![](ea029501601_ex10-1img1.jpg)

John D. Ferrell

Executive Vice President, HR

CONMED Corporation

11311 Concept Blvd.

Largo, FL 33773

May 28, 2026

John Gallagher

331 Indian Trail Drive

Franklin Lakes, NJ 07417

RE: Offer of Employment between John Gallagher and CONMED Corporation ("CONMED")<sup>1</sup>

Dear John,

I am pleased to provide this written offer to have you join CONMED as Chief Financial Officer. As we have discussed, this offer is contingent on formal approval by the Compensation Committee and Board of Directors, and your written acceptance of the terms and conditions included in this offer letter (the "Agreement"):

1. <u>Position</u>. Your position will be Executive Vice President, Chief Financial Officer, based Remotely and reporting to Pat Beyer, President and Chief Executive Officer.

2. <u>Effective Date</u>. We anticipate a start date of July 6, 2026, unless otherwise agreed ("Effective Date").

3. <u>Base Salary</u>. Beginning on the Effective Date, your annual base salary will be $650,000.00/year, paid semi-monthly (or otherwise in accordance with the CONMED's regular payroll practices).

4. <u>Annual Bonus</u>. You will be eligible to participate in our Executive Bonus Plan (as it may be amended from time to time). Your target annual bonus is 85% of your base salary. Actual bonus amounts earned, if any, are determined in CONMED's sole discretion. This bonus is subject to the terms and conditions of our Executive Bonus Plan; a copy of CONMED's current Executive Bonus Plan is being provided to you with this Agreement. Your 2026 bonus will be prorated based on (A) the target bonus multiplied by (B) a fraction equal to the number of calendar days serving as the Executive Vice President, Chief Financial Officer divided by 365 days.

5. <u>Bonus</u>. Provided that you are employed in good status on December 31, 2026, you will be paid a one-time bonus of $34,750, which shall be subject to applicable withholdings and deductions.

<sup>1</sup> Any reference to CONMED shall mean CONMED Corporation and its aﬃliated entities.

![](ea029501601_ex10-1img1.jpg)

6. <u>Long-Term Incentive Compensation</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) As of the Effective Date, you will be awarded an equity grant with a grant value of $2,300,000 comprised of 50% Restricted Stock Units ("RSUs"), 25% Performance Stock Units (at target) ("PSUs") and 25% Stock Options. All equity awards will be subject to the terms of 2025 Long-Term Incentive Plan (as it may be amended or superseded from time to time, the "Long-Term Incentive Plan") and the applicable award agreements evidencing such awards, which shall contain the terms and conditions of the awards, including the vesting provisions, and which shall control in the event of a conflict with this Section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) As of the Effective Date, in order to make you whole for certain equity awards that you are forfeiting from a prior employer, subject to the approval of the Compensation Committee, you will be awarded a one-time grant of RSUs with a grant value of $1,500,000 (the "Make-Whole RSUs"). The Make-Whole RSUs will vest in three substantially equal installments on each of the first three anniversaries of the Effective Date and will be subject to the terms of the Long-Term Incentive Plan and the award agreement evidencing such award, which shall control in the event of a conflict with this Section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) In addition, during your employment with CONMED, you will be eligible to participate in CONMED's Long-Term Incentive plan in a manner consistent with other senior leaders of the Company. The Company generally makes annual grants in March of each calendar year (which grant timing is subject to change). Subject to approval of the Compensation Committee and subject to your continued employment, on or around March 1, 2027, you will be granted long-term incentive awards for the 2027 ﬁscal year comprised of PSUs, Options and RSUs as determined by the Compensation Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) As an executive leader at CONMED, you will be subject to the Equity Ownership Guidelines established by the Board and other policies applicable to holding CONMED equity, as in effect from time to time.

7. <u>Classification and Location</u>. This is a full-time, exempt position. You will be expected to travel as necessary or requested to fulfill your responsibilities. Your employment is at-will and may be terminated by either party at any time, with or without cause.

8. <u>Paid Time Off ("PTO") Policy</u>. At CONMED we believe in the philosophy of employees working hard and living fully. CONMED's exempt PTO policy gives employees the opportunity to work or take time off as they see ﬁt, so long as the employee continues to achieve performance expectations set with their manager.

9. <u>Employee Beneﬁts; Policies</u>. You will be entitled to participate in all employee beneﬁts that CONMED has adopted or may adopt, maintain or contribute to for the beneﬁt of its executives at a level commensurate with your position subject to satisfying any applicable eligibility requirements, as such benefit plans may be in effect or amended from time to time. You will be eligible to participate in CONMED's 401(k) plan under the same terms as other participating employees. This plan currently provides a company match up to 7% of your eligible compensation, not to exceed $10,000 per year. You agree that, while employed by CONMED, you will operate with the utmost integrity and comply with all Company policies, practices and procedures and codes of ethics or business conduct, as in effect from time to time.

Page 2 of 7

![](ea029501601_ex10-1img1.jpg)

10. <u>Severance</u>. You will be eligible to participate in the CONMED Corporation Executive Severance Plan at the "Senior Executive Level" in accordance with the terms of such plan, as it may be amended and in effect from time to time.

11. <u>Covenants</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Protection of Conﬁdential Information</u>. During the term of employment and thereafter, you will (i) hold all Confidential Information in strict confidence and take all reasonable precautions to protect it from disclosure, (ii) not use or disclose such Confidential Information except as necessary to perform your duties for CONMED or as expressly authorized in writing by CONMED, and (iii) you will not, directly or indirectly, disclose or otherwise communicate Confidential Information to anyone outside of the CONMED or use Confidential Information for yourself or otherwise, either during or after the period of your employment (except as required for the proper performance of your regular duties for the Company). For purposes of this Agreement, "Confidential Information" means all non-public, proprietary, or confidential information of the CONMED, whether disclosed orally, electronically, or in writing, that you obtain or develop in the course of employment. Confidential Information includes, without limitation: financial statements (including forecasts, budgets, and liquidity analyses); earnings data and guidance; capital structure and financing arrangements; merger, acquisition, and divestiture plans; investor relations strategies; internal controls, audit materials, and compliance matters; tax strategies; pricing, cost, and margin data; supplier and customer information; intellectual property, trade secrets; business plans; strategic initiatives; Board and committee materials; and any other information that derives independent economic value from not being generally known. Upon termination of employment or upon CONMED's request at any time, you shall promptly return or destroy (at CONMED's direction) all documents, files, records, and other materials, whether in physical or electronic form, containing Confidential Information, including all copies, summaries, and extracts, and certify compliance upon request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Non-Competition</u>. During your employment with CONMED and for the period one (1) year immediately following termination of your employment with CONMED for any reason (the "Restricted Period"), you will:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i) not anywhere in the United States or any other country in which CONMED operates, directly or indirectly (whether as principal, agent, independent contractor, employee or otherwise), own, manage, organize, operate, join, control or otherwise carry on, participate in the ownership, management, organization, operation or control of, or be engaged in or concerned with, any business competitive with that of CONMED (a "Competing Business"), provided that you will not be prohibited from owning less than 5% of any publicly traded corporation, whether or not such corporation is in competition with CONMED;

Page 3 of 7

![](ea029501601_ex10-1img1.jpg)

ii) inform any person who, or entity which, seeks to engage your services that you are bound by this Section and the other terms of this Agreement; and

iii) not (x) solicit by mail, by telephone, by personal meeting, or by any other means, either directly or indirectly, any known customer or any individual or entity speciﬁcally identiﬁed as, and known to be, a prospective customer of CONMED to transact any Competing Business or to reduce or refrain from doing any business with CONMED, or (y) knowingly interfere with or damage (or attempt to interfere with or damage) any relationship between CONMED and any such customer or prospective customer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Non-Solicitation</u>. During the Restricted Period, you will not solicit, aid or induce (directly or indirectly, on your own behalf or on behalf of any individual or entity other than CONMED) any then current employee, representative or agent of CONMED to leave such employment or retention or to accept employment with or render services to or with any other person, ﬁrm, corporation or other entity unaﬃliated with CONMED or hire or retain any such employee, representative or agent, or take any action to assist or aid any other person, ﬁrm, corporation or other entity in identifying, hiring or soliciting any such employee, representative or agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Non-Disparagement</u>. While you are employed by CONMED and at all times thereafter, you agree not to make negative comments or otherwise disparage CONMED or any of its oﬃcers, directors, employees, shareholders, agents or products, in any manner likely to be harmful to them or their business, business interests, business reputation or personal reputation. Notwithstanding the foregoing, nothing herein shall prevent you from testifying truthfully in any legal or administrative proceeding where such testimony is compelled or requested, or from otherwise complying with applicable legal requirements, or limit or restrict your right to make disclosures of information as otherwise provided in subsection (e) below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Protected Activity</u>. Notwithstanding anything herein to the contrary, this Agreement shall not limit your rights under applicable law to initiate communications directly with, provide information to, respond to any inquiries from, or report possible violations of law or regulation to any governmental entity or self-regulatory authority, or to ﬁle a charge with or participate in an investigation conducted by any governmental entity or self-regulatory authority, and you do not need CONMED's permission to do so. In addition, it is understood that this Agreement shall not require you to notify CONMED of a request for information from any governmental entity or self-regulatory authority that is not directed to CONMED or of your decision to ﬁle a charge or complaint with or participate in an investigation conducted by any governmental entity or self-regulatory authority. Notwithstanding the foregoing, you recognize that, in connection with the provision of information to any governmental entity or self-regulatory authority, you must inform such governmental entity or self-regulatory authority that the information you are providing is conﬁdential. You further understand that you cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or (ii) in a complaint or other document filed under seal in a lawsuit or other proceeding; provided that, notwithstanding this immunity from liability, you understand that you may be held liable if you unlawfully access trade secrets by unauthorized means. Nothing in this Agreement shall be deemed a waiver of any applicable privilege, including the attorney-client privilege and attorney work product doctrine. The Company reserves all rights to assert such privileges. For the avoidance of doubt, this provision does not limit or restrict your rights under applicable law to communicate with any governmental entity or self-regulatory authority, including providing documents or information.

Page 4 of 7

![](ea029501601_ex10-1img1.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Remedies</u>. If you commit a breach of, or threaten to breach any of the provisions of this Section, in addition to CONMED's rights to terminate any and all of its obligations hereunder, CONMED will have the right to an injunction or order of speciﬁc enforcement, without necessity of posting a bond or providing independent evidence of irreparable injury, by any court having jurisdiction, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to CONMED, and that money damages will not provide an adequate remedy to CONMED. You and CONMED recognize that the laws and public policies of various jurisdictions may differ as to the validity and enforceability of agreements similar to those contained in this Section. It is the intention of you and CONMED that the provisions of this Section will be enforced to the fullest extent permissible under the laws and public policies of each jurisdiction in which such enforcement is sought. You and CONMED further agree that, in the event that any provision of this Section is determined by any court of competent jurisdiction to be unenforceable by reason of its being extended over too great a time, too large a geographic area or too great a range of activities, that provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g) <u>Tolling</u>. In the event of any violation of the provisions of this Section, you acknowledge and agree that the post-termination restrictions contained in this Section will be extended by a period of time equal to the period of such violation, it being the intention that the running of the applicable post-termination restriction period will be tolled during any period of such violation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h) <u>Survivability</u>. The obligations contained in this Section will survive the termination of your employment with CONMED and will be fully enforceable thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i) <u>Acknowledgement</u>. You speciﬁcally acknowledge and agree that the restrictions in this Section are necessary and reasonable for the protection of CONMED's trade secrets, Confidential Information and customer goodwill.

Page 5 of 7

![](ea029501601_ex10-1img1.jpg)

12. <u>Applicable Law; Choice of Forum</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Excepting any claim for beneﬁts under any employee beneﬁt plan in which you are a participant (which claims shall be determined in accordance with the terms of such plan), to the fullest extent permitted by law, all claims that you may have against CONMED or any other controversy arising under, or otherwise relating to, the terms of your employment with and services rendered by you to CONMED shall be governed by, and construed exclusively in accordance with, the laws of the State of New Jersey.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) The federal or state courts in New Jersey shall have exclusive jurisdiction (and shall be the exclusive forum) in the event of any claim or dispute you may raise or assert arising under or relating to the terms of your employment with and services rendered by you to CONMED.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) CONMED shall be free to bring any suit or claim relating to the enforcement of the terms of this Agreement in any court of competent jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) THE PARTIES HEREBY WAIVE ANY RIGHTS THEY MAY HAVE TO TRIAL BY JURY, INCLUDING WITHOUT LIMITATION ANY RIGHT TO TRIAL BY JURY AS TO THE MAKING, EXISTENCE, VALIDITY, OR ENFORCEABILITY OF THIS AGREEMENT.

13. <u>Forfeiture; Recoupment of Incentive Compensation</u>. All annual, long-term and other incentive compensation hereunder or pursuant to any plan, program or other agreement in which you are a participant or a party shall be subject to cancellation, forfeiture and recoupment by CONMED, and shall be repaid by you to CONMED, to the extent required by law, regulation or stock exchange listing requirement, or as may be required pursuant to any Company corporate governance guidelines or policies and to any similar or successor provisions as may be in effect from time to time. You acknowledge that you are subject to the CONMED Corporation Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation and will execute an acknowledgement provided to you by CONMED to that effect.

14. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Entire Agreement; Amendments; No Waiver</u>. This Agreement supersedes all previous agreements whether written or oral between you and CONMED and constitutes the entire agreement and understanding between CONMED and you concerning the subject matter hereof. If, and to the extent that, any other written or oral agreement between you and CONMED is inconsistent with or contradictory to the terms of this Agreement, the terms of this Agreement shall apply. No modiﬁcation, amendment, termination, or waiver of this Agreement shall be binding unless in writing and signed by you and a duly authorized oﬃcer of CONMED. Failure of any party to insist upon strict compliance with any of the terms, covenants, or conditions hereof shall not be deemed a waiver of such terms, covenants, and conditions.

Page 6 of 7

![](ea029501601_ex10-1img1.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Employment Eligibility</u>. This Agreement is contingent upon CONMED's completion of satisfactory background and reference checks, as well as its verification of your eligibility for employment within three business days of the Effective Date pursuant to the Immigration Reform and Control Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Conflicting Agreements</u>. You hereby represent and warrant that your signing of this Agreement and the performance of your obligations under it will not breach or be in conflict with any other agreement to which you are a party or are bound, and that you are not now subject to any covenants against competition or similar covenants or any court order that could affect the performance of your obligations under this Agreement. You agree that you will not disclose to or use on behalf of CONMED any confidential or proprietary information of a third party without that party's consent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Successors and Assigns</u>. This Agreement is binding upon and shall inure to the beneﬁt of you and your heirs, executors, assigns and administrators of your estate and CONMED and its successors and permitted assigns. You may not assign or transfer to others the obligation to perform your duties hereunder. The Company may not assign this Agreement other than to an affiliate or to a successor to all or substantially all of its business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Withholding</u>. All payments made by CONMED under this Agreement shall be reduced by any tax or other amounts required to be withheld by CONMED to the extent required by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Construction</u>. It is the parties' intention that this Agreement not be construed more strictly with regard to you or CONMED.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g) <u>Counterparts</u>. This Agreement may be signed in counterparts each of which will be deemed an original, but all of which will constitute one and the same instrument. This Agreement may be executed by a signature delivered by facsimile or in e-mail/PDF or other electronic format.

John, congratulations on being offered the position of Chief Financial Officer. We are very excited to have you join us.

---

| |
|:---|
| Sincerely, |
| ![](ea029501601_ex10-1img2.jpg) |
| John D. Ferrell |
| Executive Vice President, HR |

---

Page 7 of 7

## Exhibit 99.1

**Exhibit 99.1**

![](ea029501601_ex99-1img1.jpg)

---

| |
|:---|
| **NEWS RELEASE** |
| **CONTACT**: |
| ***CONMED Corporation*** |
| **Dalton Henry** |
| **Investor Relations Analyst** |
| **IR@conmed.com** |

---

**CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer**

**Largo, Fla. – June 17, 2026 – CONMED Corporation (NYSE: CNMD)** today announced the appointment of John E. Gallagher as Chief Financial Officer ("CFO"), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026.

"We are pleased to welcome a talented and experienced financial executive of John's caliber to CONMED," said Patrick J. Beyer, CONMED's President and Chief Executive Officer. "John brings deep healthcare and medical technology experience, an extensive history of public company leadership, and a proven track record of leading global finance organizations and supporting complex strategic initiatives. His combination of industry expertise, financial leadership, and operational partnership experience make him exceptionally well-positioned to help CONMED execute its strategic priorities. I am excited to work alongside John as we focus on our strategic priorities, delivering strong execution, and creating long-term value for our shareholders."

Mr. Gallagher brings nearly three decades of financial experience to CONMED, leading corporate finance, treasury, investor relations, financial planning and analysis, accounting, business performance management, and capital markets activities across public healthcare and industrial companies. Most recently, he served as CFO of Certara, Inc., a publicly traded pharmaceutical technology and services company, beginning in 2023. Prior to Certara, he served as CFO of Cue Health Inc., a healthcare technology company, from 2021 to 2023. Mr. Gallagher previously worked for Becton, Dickinson & Co. ("BD"), where he served in multiple roles over the course of 9 years. Upon joining BD in 2012, Mr. Gallagher was named Corporate Treasurer, a role he held throughout his tenure at the company. He was also responsible for corporate finance, including leading FP&A, and was Controller/Chief Accounting Officer during two transformative acquisitions. In 2018, he was promoted to Senior Vice President and CFO of BD's Medical Segment, the company's largest segment, where he partnered with leadership to drive growth, profitability, and operational performance across a global medical technology portfolio. Prior to BD, he served in various finance leadership roles at General Electric Company and Ford Motor Company. Mr. Gallagher received his MBA from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh and a B.S. in Finance from Clemson University.

"I am excited to join CONMED and look forward to working closely with Pat and the rest of the CONMED team to further enhance the Company's operating and financial performance," said John Gallagher. "CONMED has built a differentiated portfolio in high-growth surgical categories, and I look forward to partnering with Pat and the team to drive the next chapter of value creation for our shareholders."

**About CONMED Corporation** 

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

**Forward-Looking Statements**

This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.